AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02583789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
Study NCT03841149 — intervention group
Intervention type: OTHER
Intervention: Ultrasound Imaging
Description: 3D volume calculation using on-line and off-line softwares
Study NCT04159012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4).
Study NCT04159012 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4).
Study NCT04090073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: As above
Study NCT04090073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast-track Perioperative program
Description: As above
Study NCT04090073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast-track Perioperative program
Description: As above
Study NCT00999284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZK200775
Description: Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
Study NCT00999284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Intravenous infusion of sodium chloride over a period of 4 hours.
Study NCT01878513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: 3 levels of dosing dependent on which condition a patient is assigned to.
Study NCT03113435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen consumption optimization
Description: hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
Study NCT03113435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen consumption optimization
Description: hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
Study NCT01845064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199
Study NCT01484132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration of dental caries with dental composite
Description: Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
Study NCT02490410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: protein supplement
Study NCT02490410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein supplement
Study NCT03819673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group Care
Description: children's assessment, setting weight management goals, provision of personalised meal plans, personalised diet and lifestyle optimization advice recommendations to children and their families, periodic re-evaluation every 3 or 6 months
Study NCT03830775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Description: PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)
Study NCT03830775 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet-rich plasma (PRP)
Description: PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)
Study NCT04497207 — intervention group
Intervention type: OTHER
Intervention: Scheimpflug Camera Corneal Tomography
Description: Pentacam Sheimpflug system(Pentacam HR, Oculus Optikgeräte GmbH, software V.1.15r4 n7) is used for imaging of the anterir and posterior surfaces of the cornea to obtain corneal tomographic maps.
Study NCT02946983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Intragastric administration of distilled water
Study NCT03771235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention for Tics
Description: Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practices.
Study NCT04060238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anomaloscope (colour vision test)
Description: The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)
Study NCT03771235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tic Information and Coping Strategies
Description: Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
Study NCT01970943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be compared to No Intervention.
Study NCT00835822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venocur Triplex®
Description: Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
Study NCT00835822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
Study NCT02493790 — intervention group
Intervention type: OTHER
Intervention: Cognitive and motor performances
Study NCT02808650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02808650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic (PK) study
Description: Correlative studies
Study NCT02808650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Given IV
Study NCT03225274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises as Therapeutic Play
Description: On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.
Study NCT02044835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fu-zheng-qu-zhuo oral liquid
Description: Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
Study NCT03630367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intramuscular injection 8 mg
Study NCT03117972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: 12 cycles
Study NCT03117972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: 12 cycles
Study NCT03117972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: 12 cycles
Study NCT03117972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 12 cycles
Study NCT03117972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 12 cycles
Study NCT03117972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Description: Maintenance chemotherapy
Study NCT03117972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV5FU2
Description: Maintenance chemotherapy
Study NCT03117972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Maintenance chemotherapy
Study NCT03117972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Maintenance chemotherapy
Study NCT01568905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level nicotine cigarette
Description: smoke the study cigarette exclusively for one week
Study NCT01568905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermediate nicotine level cigarette
Description: smoke the study cigarette exclusively for one week
Study NCT01568905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High level nicotine cigarette
Description: smoke the study cigarette exclusively for one week
Study NCT01845064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03630367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intramuscular injection 8 mg
Study NCT03630367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine 1G/5mL Injection
Description: slow intravenous injection
Study NCT04598464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercise
Description: The home-based training program included posture and stretching exercises, strengthening exercises, balance training, and a walking regimen 3 days per week for 3 months.
Study NCT00892658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
Study NCT03637179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
Study NCT03637179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study NCT01419639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001) , Afinitor®
Description: Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
Study NCT01672736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7487, Velcade, Dexamethasone
Description: ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
Study NCT01497327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-352938
Description: PSI-352938 300mg once daily (QD) for seven days
Study NCT01497327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: PSI-7977 400mg QD for seven days
Study NCT00904306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: placebo oral tablet taken once per day
Study NCT00904306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chromium picolinate
Description: 1000 ug/day chromium picolinate for 6 months
Study NCT00904306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chromium picolinate
Description: 600 ug/day chromium picolinate
Study NCT05462470 — intervention group
Intervention type: PROCEDURE
Intervention: Repeat Liver Surgery
Description: repeat liver surgery included not only hepatectomy, but also ablative treatment, including radiofrequency ablation (RFA) and microwave ablation (MWA)
Study NCT05462470 — intervention group
Intervention type: PROCEDURE
Intervention: Non-Repeat Liver Surgery
Description: Systemic palliative chemotherapy
Study NCT03008538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPM(Mineralized plasmatic matrix).
Description: Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
Study NCT03008538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone Graft
Description: Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
Study NCT00560326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Ointment 0.03%
Description: Once or twice daily topical application
Study NCT01259830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arcoxia®120 mg
Description: Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
Study NCT01259830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P Tablet White Lichtenstein
Description: P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
Study NCT01174667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific massage for fascial release
Description: Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
Study NCT01174667 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Quiet non-instructed rest for 3 minutes
Description: Patient will lay quietly without any instructions on how to relax.
Study NCT02243137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: Administration: one dose of Acetylsalicylic Acid (300mg)
Study NCT02243137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: Administration: one loading dose (60mg)
Study NCT02465112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In111-Pentetréotide
Study NCT02465112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: simple monitoring without active therapy
Study NCT03364790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PLIF
Description: Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
Study NCT04301388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound to measure cervical length if persist regular uterine contraction
Study NCT04301388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound to measure cervical length if persist regular uterine contraction
Study NCT02896608 — intervention group
Intervention type: DEVICE
Intervention: measure of neuronal excitability
Study NCT00599677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
Study NCT03364790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKA
Description: Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
Study NCT00424801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Description: Individual titration, max. dose 20 mg OD for 8 months
Study NCT00424801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Individual titration, max. dose 160 mg OD for 8 months
Study NCT00424801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: Individual titration, max. dose 20 mg BD for 8 months
Study NCT00424801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Individual titration, max. dose 4 mg OD for 8 months
Study NCT00424801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidin
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
Study NCT00424801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pindolol
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
Study NCT00424801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride, hydrochlorothiazide
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
Study NCT03391310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey (medicated)
Description: Honey (medicated) dressing will be used in the experimental group
Study NCT04093414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Select Secure pacing lead
Description: A Select Secure pacing lead is placed in the bundle of His or Left bundle branch area based upon randomization
Study NCT02243137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: Administration: one loading dose (60mg)
Study NCT02243137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lysine acetylsalicylate
Description: Administration: one dose (450mg iv)
Study NCT03275857 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Weekly IV